Advertisement
Advertisement
TOPIC

Biomedicine: Science

Related Topics:
Biomedicine: Science
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
Researchers have engineered brewer’s yeast to produce catharanthine – the direct precursor to the cancer treatment vinblastine. Photo: Getty Images/iStockphoto
Science

Chinese ‘yeast factory’ boosts cancer drug production by 1,000 times

Turning point comes from cross-disciplinary collaboration, including across plant biochemistry, synthetic biology and protein engineering.

videocam
China’s private sector

China’s drug firms set to compete on the world stage, analysts say

4
China’s private sector

Sugar for the pill: US$8b fund boosts Hong Kong’s biotech hub ambitions

Banking & finance

As weight-loss drug orders surge, global funds pile into China’s WuXi AppTec

Pharmaceutical contractor’s GLP-1 programmes and surging stock gains have made it a magnet for global investors.

WuXi AppTec was expected to release its half-year earnings results on August 3. Photo: Handout
Banking & finance

Healthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listing

Axiom Biosciences founder says Hong Kong investors show greater maturity than Nasdaq in handling biotech companies.

China’s private sector

China’s biotech boom: RAS-targeted drugs challenge US dominance

The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.

Advertisement
Advertisement
Advertisement
China’s private sector

China AI drug-design deals swell as US scrutiny mounts

Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.

videocam
Industry insiders say AI-powered drug-design tools have the potential to shorten development timelines from years to as few as 18 months. Photo: Shutterstock
Medicine

China closing in but US leads in biotech quality and commercial reach: survey

The Cure survey said China leads ⁠in clinical development and supply chain, and rated US funding cuts a bigger threat than China competition.

videocam
China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

China’s private sector

With AI able to predict disease, can we treat ageing like a ‘bug’ in the system?

AI is transforming longevity as companies like METiS TechBio and Human Longevity use algorithms to combat ageing and predict health risks.

Illustration: Lau Ka-kuen
Science

Biomedicine | China steps up Alzheimer’s, Parkinson’s drug push, looks to TCM

With the most cases of the two leading neurodegenerative diseases, and affected population rising as country ages, China needs to find new treatments.

China steps up Alzheimer’s, Parkinson’s drug push, looks to TCM
Biomedicine: Companies

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.

videocam
Science

Chinese team uses supercomputer to cut drug screening time from years to seconds

AI platform that can screen vast library of chemical compounds opens up new frontiers in fight against cancer and infectious diseases.

videocam
China’s private sector

Insilico, US partner to build AI models predicting disease decades ahead

Tie-up combines Hong Kong-listed Insilico Medicine’s algorithms with Human Longevity’s genomic data to advance personalised health research.

The global longevity market, fuelled by an ageing population and rising consumption demand, is currently valued at US$5.3 trillion, according to a UBS report. Photo: Shutterstock
Science

Chinese scientists grow heart’s ‘master conductor’ that could replace pacemaker

Shanghai researchers engineer biological pacemaker that could offer a new way to control abnormal heart rhythms.

videocam
The findings of Chinese scientists may offer possibilities for future biological pacemaker strategies, according to their paper. Image: Shutterstock
US-China relations

As I see it | US’ scientific self-harm will only help China

While Washington slashes funding for the sciences, Beijing is clinching its lead in everything from patent applications to publications.

videocam
16
Biomedicine: Companies

China biotech deals hit record as innovative drugs draw global interest

Deals reach US$60 billion in first quarter after analysts say Chinese biotech firms have shown substantial technological advancements.

Advertisement
Advertisement
Advertisement
Biomedicine: Companies

In a first for China, Neuracle’s brain-computer interface wins approval

China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.

A man demonstrates a robotic hand with a brain-computer interface at the China International Import Expo on November 7, 2025. Neuracle’s regulatory milestone underscores China’s accelerating push in neurotechnology. Photo: AFP
Science

Chinese gene-editing technique raises prospect of new autism treatments

Lab tests on mice given the treatment showed considerable cognitive and behavioural functions, new study says.

videocam
US-China relations

Opinion | China has Trump 2.0 to thank for emerging stronger in tech and trade

As intense US-China competition becomes the new normal, pressure has strengthened China’s capacity to adapt rather than deter it from its long-term ambitions.

videocam
Science

Structural biologist Alexey Amunts launches new research lab in Shenzhen

‘Shenzhen adds another dimension; it is a place where ideas do not remain ideas for long,’ Amunts says of new position.

videocam
8
Alexey Amunts, who is internationally recognised for his breakthroughs in visualising life’s molecular machinery at near-atomic resolution, has joined China’s SMART academy in Shenzhen. Photo: Mia Zhao
Made in China 2025

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Swiss drugmaker Novartis has gained global rights over SciNeuro’s novel amyloid beta targeted antibody programme. Photo: Reuters
Insilico

Insilico signs US$888 million AI drug deal days after Hong Kong IPO

Multi-year partnership with France’s Servier will use Insilico’s AI platform to explore novel cancer drugs.

Science

China’s biopharma sector ‘in prime position to challenge US leadership’

American commission issues stark warning, as analytics firm Clarivate reports that Chinese innovative drug development has entered new phase.

videocam
33
IPO

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.

Insilico is training and testing an AI-powered drug-discovery tool to enable faster, cheaper and more successful drug discovery. Photo: Handout
Made in China 2025

China’s rising biotech clout on show in flurry of billion-dollar licensing deals

A burst of overseas licensing pacts is spotlighting China’s biotech sector, as Jacobio, Coherent Biopharma and Harbour BioMed land deals.

The latest transactions reflect a broader pattern of multinational drugmakers turning to Chinese biotechs for pipeline replenishment. Photo: Shutterstock
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Science

How Chinese scientists turn allergy into a powerful weapon against cancer

Mast cell platform can expand to carry other payloads, such as molecules, viruses, proteins and drug-loaded nanoparticles.

videocam
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement